Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.
The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.